公开(公告)号：US20070059730A1

公开(公告)日：2007-03-15

申请号：US11445606

申请日：2006-06-02

申请人： Rory Curtis ,  Thomas Logan ,  Maria Glucksmann ,  Rachel Meyers ,  Mark Williamson ,  Laura Rudolph-Owen ,  Miyoung Chun ,  Fong-Ying Tsai

发明人： Rory Curtis ,  Thomas Logan ,  Maria Glucksmann ,  Rachel Meyers ,  Mark Williamson ,  Laura Rudolph-Owen ,  Miyoung Chun ,  Fong-Ying Tsai

IPC分类号： C12Q1/68 ,  C07H21/04 ,  C12P21/06 ,  C12N9/00 ,  C07K14/705

CPC分类号： C07K14/705 ,  A01K2217/05 ,  A61K38/00 ,  C07K14/395 ,  C07K14/43545 ,  C07K14/43581 ,  C07K14/43595 ,  C07K14/463 ,  C07K14/465 ,  C07K14/47 ,  C07K2319/00 ,  C12N9/00 ,  C12N9/0071 ,  C12N9/0083 ,  C12N9/1205 ,  C12N9/18 ,  C12N9/20 ,  C12N9/88 ,  C12N2310/3513 ,  C12Y207/01001 ,  C12Y301/04003

摘要： The invention provides isolated nucleic acids molecules, designated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 gene has been introduced or disrupted. The invention still further provides isolated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 proteins, fusion proteins, antigenic peptides and anti-25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

摘要翻译： 本发明提供分离的核酸分子，命名为25869,25934,26335,50516,21117,38692,46508,16816,16839,49937,49931和49933核酸分子。 本发明还提供反义核酸分子，包含25869,25934,26335,50521,21117,38692,46508,16816,16839,4467,49931或49933核酸分子的重组表达载体，已经引入了表达载体的宿主细胞 ，以及引入或破坏25869,25934,26335,50365,21117,38692,46508,16816,16839,49937,49931或49933基因的非人类转基因动物。 本发明还进一步提供了分离的25869,2593,26335,50365,21117,38692,46508,16816,16839,49937,49931或49933蛋白，融合蛋白，抗原肽和抗-25869,25934,26335,50365,211117,38692 ，46508,16816,16839,49937,49931或49933抗体。 还提供了利用本发明组合物的诊断和治疗方法。

公开(公告)号：US20070087375A1

公开(公告)日：2007-04-19

申请号：US11633986

申请日：2006-12-05

申请人： John Hunter ,  Mark Williamson ,  Kyle MacBeth ,  Laura Rudolph-Owen ,  Fong-Ying Tsai

发明人： John Hunter ,  Mark Williamson ,  Kyle MacBeth ,  Laura Rudolph-Owen ,  Fong-Ying Tsai

IPC分类号： C12Q1/68 ,  G01N33/574

CPC分类号： G01N33/5011 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N2500/04 ,  G01N2500/10

摘要： The present invention relates to methods for the diagnosis and treatment of a cancer or cancer. Specifically, the present invention identifies the differential expression of 2192, 2193, 6568, 8895, 9138, 9217, 9609, 9857, 9882, 10025, 20657, 21163, 25848, 25968, 32603, 32670, 33794, 54476 and 94710 genes in tissues relating to cancer, relative to their expression in normal, or non-cancer disease states, and/or in response to manipulations relevant to a cancer. The present invention describes methods for the diagnostic evaluation and prognosis of various cancers, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating a cancer or cancer. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of cancer.

摘要翻译： 本发明涉及癌症或癌症的诊断和治疗方法。 具体而言，本发明鉴定组织中的2192,2133,6568,8895,9138,9217,9609,9857,9882,10025,20657,21163,25848,25968,32603,32670,3797,45476和94710基因的差异表达 涉及癌症，相对于它们在正常或非癌症疾病状态中的表达，和/或响应于与癌症相关的操作。 本发明描述了各种癌症的诊断评估和预后的方法，以及用于鉴定表现出这种病症倾向的受试者。 本发明还提供了鉴定能够调节癌症或癌症的化合物的方法。 本发明还提供了鉴定和治疗化合物作为癌症治疗的方法。

公开(公告)号：US20070078088A1

公开(公告)日：2007-04-05

申请号：US11603696

申请日：2006-11-22

申请人： John Hunter ,  Kyle MacBeth ,  Fong-Ying Tsai ,  Andrea Lesoon ,  Eric Lightcap ,  Mark Williamson ,  Laura Rudolph-Owen

发明人： John Hunter ,  Kyle MacBeth ,  Fong-Ying Tsai ,  Andrea Lesoon ,  Eric Lightcap ,  Mark Williamson ,  Laura Rudolph-Owen

IPC分类号： A61K38/17 ,  A61K48/00 ,  C12Q1/68 ,  G01N33/574

CPC分类号： G01N33/574 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/5011 ,  G01N2500/00

摘要： The present invention relates to methods for the diagnosis and treatment of a cancer or cancer. Specifically, the present invention identifies the differential expression of 140, 1470, 1686, 2089, 2427, 3702, 5891, 6428, 7181, 7660, 25641, 69583, 49863, 8897, 1682, 17667, 9235, 3703, 14171, 10359, 1660, 1450, 18894, 2088, 32427, 2160, 9252, 9389, 1642, 85269, 10297, 1584, 9525, 14124, 4469, 8990, 2100, 9288, 64698, 10480, 20893, 33230, 1586, 9943, 16334, 68862, 9011, 14031, 6178, 21225, 1420, 32236, 2099, 2150, 26583, 2784, 8941, 9811, 27444, 50566 and 66428 genes in tissues relating to cancer, relative to their expression in normal, or non-cancer disease states, and/or in response to manipulations relevant to a cancer. The present invention describes methods for the diagnostic evaluation and prognosis of various cancers, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating a cancer or cancer. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of cancer.

摘要翻译： 本发明涉及癌症或癌症的诊断和治疗方法。 具体地说，本发明鉴定了140,1470,1686,2089,2427,3702,5891,62828,7181,7660,25641,69583,49863,8897,1682,17676,92935,3703,14171,10359的差异表达， 1660,1450,18894,2088,32427,2160,9252,9389,1642,85269,10297,1584,9525,14124,4469,8990,2100,92988,64698,104080,20893,33230,1586,99943,16334， 68862,9011,14031,6178,21225,1420,32236,2099,2150,26583,2784,8891,99811,27444,50566和66428个基因在与癌症有关的组织中相对于它们在正常或非癌症疾病中的表达 状态和/或响应于与癌症相关的操作。 本发明描述了各种癌症的诊断评估和预后的方法，以及用于鉴定表现出这种病症倾向的受试者。 本发明还提供了鉴定能够调节癌症或癌症的化合物的方法。 本发明还提供了鉴定和治疗化合物作为癌症治疗的方法。

公开(公告)号：US20060088907A1

公开(公告)日：2006-04-27

申请号：US10370959

申请日：2003-02-20

申请人： Rachel Meyers ,  Mark Williamson ,  Rosana Kapeller-Libermann ,  Kyle MacBeth ,  John Hunter ,  Laura Rudolph-Owen ,  Rajasekhar Bandaru ,  Fong-Ying Tsai

发明人： Rachel Meyers ,  Mark Williamson ,  Rosana Kapeller-Libermann ,  Kyle MacBeth ,  John Hunter ,  Laura Rudolph-Owen ,  Rajasekhar Bandaru ,  Fong-Ying Tsai

IPC分类号： C07K14/705 ,  C12P21/02 ,  C12N5/06 ,  C07H21/04

CPC分类号： C12N9/1205 ,  A01K2217/05 ,  A61K48/00 ,  C07K2319/00

摘要： The invention provides isolated nucleic acids molecules, designated 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 and 32252 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 and 32252 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 or 32252 gene has been introduced or disrupted. The invention still further provides isolated 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 or 32252 proteins, fusion proteins, antigenic peptides and anti-13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 or 32252 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

公开(公告)号：US20060088880A1

公开(公告)日：2006-04-27

申请号：US11300765

申请日：2005-12-15

申请人： Mark Williamson ,  Laura Rudolph-Owen

发明人： Mark Williamson ,  Laura Rudolph-Owen

IPC分类号： C12Q1/68 ,  A61K39/395 ,  G01N33/574 ,  A61K48/00 ,  A61K38/17

CPC分类号： G01N33/5011 ,  C07K14/47

摘要： The present invention relates to methods and compositions for the treatment and diagnosis of cellular proliferation disorders, including, but not limited to, breast cancer, ovarian cancer, lung cancer, and colon cancer. The invention further provides methods for identifying a compound capable of treating a cellular proliferation disorders disorder or modulating cellular proliferation. The invention also provides a method for modulating cellular proliferation, e.g., modulating cellular proliferation in a subject. In addition, the invention provides a method for treating a subject having a cellular proliferation disorder characterized by aberrant 25943 polypeptide activity or aberrant 25943 nucleic acid expression.

公开(公告)号：US20070037203A1

公开(公告)日：2007-02-15

申请号：US11583766

申请日：2006-10-19

申请人： Rosana Kapeller-Libermann ,  John Hunter ,  Rachel Meyers ,  Laura Rudolph-Owen ,  Rory Curtis ,  Peter Olandt ,  Fong-Ying Tsai ,  Katherine Galvin ,  Miyoung Chun ,  Mark Williamson ,  Inmaculada Silos-Santiago ,  Rajasekhar Bandaru

发明人： Rosana Kapeller-Libermann ,  John Hunter ,  Rachel Meyers ,  Laura Rudolph-Owen ,  Rory Curtis ,  Peter Olandt ,  Fong-Ying Tsai ,  Katherine Galvin ,  Miyoung Chun ,  Mark Williamson ,  Inmaculada Silos-Santiago ,  Rajasekhar Bandaru

IPC分类号： C12Q1/68 ,  C07H21/04 ,  A61K48/00 ,  C07K14/705

CPC分类号： C07K14/47 ,  A01K2217/05 ,  C12N9/1235

摘要： The invention provides isolated nucleic acids molecules, designated 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 and 593 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 and 593 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 or 593 gene has been introduced or disrupted. The invention still further provides isolated 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 or 593 proteins, fusion proteins, antigenic peptides and anti-21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 or 593 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

摘要翻译： 本发明提供分离的核酸分子，命名为21910,5663,55053,2504,15977,14760,25501,17903,3720,21529,26176,26343,5663,18610,33217,21967，h1983，m1983,38555和593核酸 分子。 本发明还提供反义核酸分子，含有21910,5663,55053,2504,15977,14760,25501,17903,3700,21529,26176,26343,5663,18610,33217,21967，h1983，m1983,3855的重组表达载体 和593个核酸分子，其中引入了表达载体的宿主细胞，以及非人类转基因动物，其中21910,5663,5553,2504,15977,14760,25501,17903,3720,21529,26176， 已经引入或破坏了18610,33217,21967，h1983，m1983,38555或593基因。 本发明还进一步提供分离的21910,5563,4560,25501,17903,3720,21529,26176,26343,5663,18610,33217,21967，h1983，m1983,38555或593蛋白，融合蛋白， 抗原肽和抗-19910,563634,55053,2504,15977,14760,25501,17903,3720,21529,26176,26343,56638,18610,33217,21967，h1983，m1983,38555或593抗体。 还提供了利用本发明组合物的诊断和治疗方法。

公开(公告)号：US20060166326A1

公开(公告)日：2006-07-27

申请号：US11335810

申请日：2006-01-19

申请人： Rachel Meyers ,  William Cook ,  Mark Williamson ,  Laura Rudolph-Owen ,  Ruth Gimeno

发明人： Rachel Meyers ,  William Cook ,  Mark Williamson ,  Laura Rudolph-Owen ,  Ruth Gimeno

IPC分类号： C07H21/04 ,  C12P21/06 ,  C12N9/04

CPC分类号： C12N9/0004 ,  C07K2319/00 ,  C12N9/0006

摘要： The invention provides isolated nucleic acids molecules, designated DHDR nucleic acid molecules, which encode novel DHDR-related dehydrogenase molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing DHDR nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DHDR gene has been introduced or disrupted. The invention still further provides isolated DHDR proteins, fusion proteins, antigenic peptides and anti-DHDR antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

公开(公告)号：US20060116508A1

公开(公告)日：2006-06-01

申请号：US11313836

申请日：2005-12-21

申请人： Maria Glucksmann ,  Mark Williamson ,  Fong-Ying Tsai ,  Laura Rudolph-Owen ,  Rosanna Kapeller-Libermann ,  Rachel Meyers ,  Lillian Chiang ,  John Hunter

发明人： Maria Glucksmann ,  Mark Williamson ,  Fong-Ying Tsai ,  Laura Rudolph-Owen ,  Rosanna Kapeller-Libermann ,  Rachel Meyers ,  Lillian Chiang ,  John Hunter

IPC分类号： C07H21/04 ,  C12P21/06 ,  C12N9/16

CPC分类号： C12N9/1288 ,  A01K2217/05 ,  A61K38/00 ,  A61K47/6805 ,  A61K47/6809 ,  A61K47/6821 ,  A61K48/00 ,  A61K2039/505 ,  C07K14/4747 ,  C07K2319/00 ,  C12N9/14 ,  C12N9/16 ,  C12N9/6472 ,  G01N33/5011 ,  G01N33/57407 ,  G01N33/57484 ,  G01N2500/10

摘要： The invention provides isolated nucleic acids molecules and proteins, designated 27411, 23413, 22438, 23553, 25278, 26212, NARC SC1, NARC 10A, NARC 1, NARC 12, NARC 13, NARC17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC 1C, NARC 1A, NARC 25, 86604 and 32222 nucleic acid molecules and proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing said nucleic acid molecules, host cells into which the expression vectors have been introduced, nonhuman transgenic animals in which a said genes have been introduced or disrupted, fusion proteins, antigenic peptides and antibodies to said proteins. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

摘要翻译： 本发明提供分离的核酸分子和蛋白质，命名为27411,23413,22438,23553,25278,26212，NARC SC1，NARC 10A，NARC 1，NARC 12，NARC 13，NARC 17，NARC 25，NARC 3，NARC 4，NARC 7，NARC 8，NARC 11，NARC 14A，NARC 15，NARC 16，NARC 19，NARC 20，NARC 26，NARC 27，NARC 28，NARC 30，NARC 5，NARC 6，NARC 9，NARC 10C，NARC 8B， NARC 9，NARC2A，NARC 16B，NARC 1C，NARC 1A，NARC 25，86604和32222核酸分子和蛋白质。 本发明还提供了反义核酸分子，含有所述核酸分子的重组表达载体，其中引入了表达载体的宿主细胞，其中所述基因已导入或破坏的非人类转基因动物，融合蛋白，抗原肽和抗体 到蛋白质。 还提供了利用本发明组合物的诊断和治疗方法。

公开(公告)号：US08926561B2

公开(公告)日：2015-01-06

申请号：US12846734

申请日：2010-07-29

申请人： Erik T. Verhoef ,  Paul M. DiPerna ,  Mike Rosinko ,  Mark Williamson ,  Geoffrey A. Kruse ,  Thomas R. Ulrich ,  Phil Lamb ,  Sean Saint ,  Michael Michaud ,  William Trevaskis

发明人： Erik T. Verhoef ,  Paul M. DiPerna ,  Mike Rosinko ,  Mark Williamson ,  Geoffrey A. Kruse ,  Thomas R. Ulrich ,  Phil Lamb ,  Sean Saint ,  Michael Michaud ,  William Trevaskis

IPC分类号： A61M37/00 ,  A61M5/142 ,  A61M5/14 ,  A61M5/168 ,  G06F3/0488

CPC分类号： A61M5/172 ,  A61M5/1413 ,  A61M5/14244 ,  A61M5/14248 ,  A61M5/16804 ,  A61M5/1723 ,  A61M5/31513 ,  A61M2005/14268 ,  A61M2205/3389 ,  A61M2205/50 ,  A61M2205/505 ,  A61M2205/52 ,  A61M2230/201 ,  A61M2230/63 ,  F04B43/113 ,  F04B53/143 ,  F16J15/32 ,  F16J15/56 ,  G06F3/0488 ,  G06F19/00 ,  G16H40/63

摘要： Embodiments are directed to portable infusion devices, systems, and methods of using the same for dispensing materials. In some cases, the devices, systems and methods may be used for infusing a material such as medicament, e.g., insulin, into a body in need thereof.

摘要翻译： 实施例涉及便携式输注装置，系统以及使用其来分配材料的方法。 在一些情况下，装置，系统和方法可以用于将诸如药物（例如胰岛素）的材料注入到有需要的身体中。

公开(公告)号：US20130183876A1

公开(公告)日：2013-07-18

申请号：US13742853

申请日：2013-01-16

申请人： Todd B. Veselis ,  David E. Cobb ,  Thomas M. Fulton ,  Mark Williamson

发明人： Todd B. Veselis ,  David E. Cobb ,  Thomas M. Fulton ,  Mark Williamson

IPC分类号： B63B22/02

CPC分类号： B63B22/02 ,  B63B35/4413 ,  B63B2022/028 ,  B63B2241/10

摘要： Releasable mooring systems and methods for drilling vessels that may be implemented with dockable and releasable mooring buoys to provide for both a quick disconnect of the mooring system from a drilling vessel and for re-connection of the drilling vessel when the vessel returns to the well site.

摘要翻译： 用于钻井船舶的可释放的系泊系统和方法，其可以用可停靠和可释放的系泊浮标来实施，以提供系泊系统与钻井容器的快速断开以及当船舶返回到井场时重新连接钻井船 。